Ardelyx Stock Forecast, Price & News

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ardelyx stock.
View analyst ratings for Ardelyx or view top-rated stocks.

Wall Street analysts have given Ardelyx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ardelyx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Ardelyx is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Ardelyx.

Ardelyx, Inc. (NASDAQ:ARDX) announced its earnings results on Thursday, August, 12th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.09. Ardelyx had a negative net margin of 1,009.33% and a negative trailing twelve-month return on equity of 99.11%.
View Ardelyx's earnings history.

Ardelyx's stock was trading at $5.98 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ARDX shares have decreased by 78.1% and is now trading at $1.31.
View which stocks have been most impacted by COVID-19.

8 analysts have issued 1-year price targets for Ardelyx's shares. Their forecasts range from $2.00 to $15.00. On average, they anticipate Ardelyx's stock price to reach $7.46 in the next year. This suggests a possible upside of 469.7% from the stock's current price.
View analysts' price targets for Ardelyx or view top-rated stocks among Wall Street analysts.

Some companies that are related to Ardelyx include Inventiva (IVA), Intercept Pharmaceuticals (ICPT), Viking Therapeutics (VKTX), Theravance Biopharma (TBPH), Catalyst Pharmaceuticals (CPRX), Zomedica (ZOM), Selecta Biosciences (SELB), SIGA Technologies (SIGA), AC Immune (ACIU), Akebia Therapeutics (AKBA), Verastem (VSTM), Eliem Therapeutics (ELYM), Aldeyra Therapeutics (ALDX), Clene (CLNN) and Basilea Pharmaceutica (BPMUF).
View all of ARDX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD).

Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."

Ardelyx's stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (6.36%), BlackRock Inc. (6.30%), Vanguard Group Inc. (3.95%), Redmile Group LLC (3.76%), Marshall Wace LLP (3.39%) and Marshall Wace LLP (3.25%). Company insiders that own Ardelyx stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Mark Kaufmann, Michael Raab, Robert Blanks, Scott D Sandell and Susan Rodriguez.
View institutional ownership trends for Ardelyx.

ARDX stock was sold by a variety of institutional investors in the last quarter, including Prudential Financial Inc., Thrivent Financial for Lutherans, Pekin Hardy Strauss Inc., Allianz Asset Management GmbH, 683 Capital Management LLC, Bailard Inc., Price T Rowe Associates Inc. MD, and Vanguard Group Inc.. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Jeffrey W Jacobs, and Michael Raab.
View insider buying and selling activity for Ardelyx or view top insider-selling stocks.

ARDX stock was acquired by a variety of institutional investors in the last quarter, including State Street Corp, Orchard Capital Managment LLC, Millennium Management LLC, Congress Asset Management Co. MA, Deutsche Bank AG, Marshall Wace LLP, Marshall Wace LLP, and BlackRock Inc..
View insider buying and selling activity for Ardelyx or or view top insider-buying stocks.

Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARDX stock can currently be purchased for approximately $1.31.

Ardelyx has a market capitalization of $135.09 million and generates $7.57 million in revenue each year. The biopharmaceutical company earns $-94,310,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

Ardelyx employs 129 workers across the globe.

The official website for Ardelyx is www.ardelyx.com.

Ardelyx is headquartered at 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555.

Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at (510) 745-1700 or via email at [email protected]